Mesenchymal stem cells (MSCs), which are an emerging cell therapeutic for inflammatory bowel disease (IBD), have demonstrated immunomodulatory effects through interactions with T cells and dendritic cells (DCs).
Mesenchymal stem cells (MSCs), which are an emerging cell therapeutic for inflammatory bowel disease (IBD), have demonstrated immunomodulatory effects through interactions with T cells and dendritic cells (DCs).